DocWire News Editors

DocwireNews

A study assessed the feasibility, toxicity, and activity of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients with localized muscle invasive bladder cancer (MIBC). The results of the phase II IMMUNOPRESERVE-SOGUG trial were presented during the 2021 ASCO Annual Meeting.&ldquo;Bladder-preserving combined modality therapies constitute an alternative to radical cystectomy for selected patients with MIBC. In preclinical studies, combination of radiation and dual checkpoint blockade appears to activate non-redundant immune mechanisms, potentiating antitumor activity,&rdquo; the researchers explained.They evaluated patients with localized MIBC in clinical stages T2-4a who had no contraindications to immunotherapy who either wanted bladder preservation or could not undergo cystectomy. Patients received initial transurethral resection (TUR) of the tumor, followed by durvalumab 1,500 mg intravenously (IV) plus tremelimumab 75 mg IV, every four weeks for three doses. Two weeks later, they began normofractionated external-beam RT (46 Gy to minor pelvis, 64-66 Gy to bladder). The primary endpoint was complete response (CR).Final analysis included 32 patients at six centers with a median age of 71 years who underwent at least two immunotherapy cycles. At post-treatment biopsy, 26 patients attained CR, two patients had residual MIBC, and four patients were not evaluated due to rejection, clinical impairment, death from COVID-19, and a suspected treatment-related death from peritonitis (n=1 for all).Median follow-up was 6.1 months, at which time two patients required salvage cystectomy. The estimated six-month disease-free survival (DFS) rate with bladder intact was 76%, DFS was 80%, and overall survival was 93%. The most common adverse events (AEs) related to RT and/or immunotherapy were diarrhea (41%) and urinary disorders (37.5%). Overall, 31% of patients experienced grade 3 or 4 AEs, the most common of which were gastrointestinal toxicity (12.5%), acute kidney failure (6%) and hepatitis (6%).

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Durvalumab Plus Tremelimumab With Concurrent Radiotherapy in Bladder Cancer

ASCO 2021

Researchers evaluated patients with localized MIBC in clinical stages T2-4a who had no contraindications to immunotherapy.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe